ArticleResearch square2026
AI-Driven Bone and Marrow Segmentation on FLT-PET/CT: Technical Multi-organ Validation in AML and HCT.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03422731 (Multi-Modality Imaging and Correlative Studies in Patients With Leukemia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-Modality Imaging and Correlative Studies in Patients With Leukemia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: [18F] 3'-deoxy-3'-fluorothymidine positron emission tomography (FLT-PET) is valuable for detecting acute myeloid leukemia (AML) and monitoring stem cell engraftment after hematopoietic stem cell transplant (HCT) by assessing cellular proliferation in marrow-rich tissues. Reliable marrow quantification is difficult to achieve, and manual segmentation is impractical in clinical workflows. Most automated tools focus on solid tumors and lack clinical validation for skeletal FLT-PET/CT. This study evaluates deep learning whole-body segmentation and cortical-trabecular marrow quantification on FLT-PET/CT in AML with HCT. Results: Twenty refractory AML patients undergoing total marrow and lymphoid irradiation (TMLI) and transplantation were analyzed. From 134 predefined regions, five representative ROIs (spleen, liver, T6, L1, L3) validated agreement with manual segmentation. Automated and manual count measurements showed strong agreement, with a high correlation (r > 0.98, p < 0.0001). Consistent hotspot detection by both methods supports the AI tool's accuracy and clinical applicability. Small liver/spleen differences and larger positive vertebral trabecular biases were observed. AI cut processing time by ~ 95%, markedly improving efficiency. Conclusion: This study provides a technical validation of an AI-driven multi-organ segmentation platform for FLT-PET/CT in AML and HCT, including separate cortical bone and trabecular marrow compartments. The automated approach demonstrated high agreement, excellent reproducibility, and substantial efficiency gains in skeletal marrow and organ quantification. These findings establish a scalable framework for future studies that will correlate FLT-based bone marrow metrics with clinical response and transplant outcomes. Trial registration: ClinicalTrials.gov NCT03422731. Registered 6 February 2018, https//www.cancer.gov/research/participate/clinicaltrialssearch/v?id=NCI201701778.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.